114027
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.4 Breast Cancer (Dove Med Press)
- 3.2 Clin Epidemiol
- 2.6 Cancer Manag Res
- 2.9 Infect Drug Resist
- 3.7 Clin Interv Aging
- 5.1 Drug Des Dev Ther
- 3.1 Int J Chronic Obstr
- 6.6 Int J Nanomed
- 2.6 Int J Women's Health
- 2.9 Neuropsych Dis Treat
- 2.8 OncoTargets Ther
- 2.0 Patient Prefer Adher
- 2.2 Ther Clin Risk Manag
- 2.5 J Pain Res
- 3.0 Diabet Metab Synd Ob
- 3.2 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 1.8 Pharmgenomics Pers Med
- 2.0 Risk Manag Healthc Policy
- 4.1 J Inflamm Res
- 2.0 Int J Gen Med
- 3.4 J Hepatocell Carcinoma
- 3.0 J Asthma Allergy
- 2.2 Clin Cosmet Investig Dermatol
- 2.4 J Multidiscip Healthc
已发表论文
苦参碱及其衍生物：癌症治疗中的多途径调节作用
Received 26 August 2025
Accepted for publication 18 December 2025
Published 24 December 2025 Volume 2025:17 Pages 3285—3297
DOI https://doi.org/10.2147/CMAR.S563211
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Professor Harikrishna Nakshatri
Zitong Xiong, Jiangtao Pu
Department of Thoracic Surgery, Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan Province, 646600, People’s Republic of China
Correspondence: Jiangtao Pu, Department of Thoracic Surgery, Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan Province, 646600, People’s Republic of China, Email 19164172037@163.com
Abstract: Matrine and its derivatives, as multi-target natural alkaloids, exhibit synergistic antitumor effects through the regulation of core oncogenic pathways including Wnt/β-catenin, MAPK/ERK, and PI3K/AKT/mTOR. These compounds inhibit tumor proliferation by suppressing epithelial-mesenchymal transition (EMT), inducing programmed cell death (apoptosis, autophagy, and pyroptosis), and remodeling the tumor immune microenvironment. Preclinical studies demonstrate that third-generation derivatives (e.g.MT-26, YF-18) enhance therapeutic efficacy by targeting DNMT1/HDAC6 dual inhibition and activating the NLRP3/caspase-1 pyroptosis pathway, achieving tumor suppression rates of 60– 78% in pancreatic and liver cancer patient-derived xenograft (PDX) models while overcoming chemotherapy resistance. However, preclinical-to-clinical translation faces challenges such as low bioavailability, off-target toxicity (e.g.hepatotoxicity via JNK/c-Jun activation), and tumor heterogeneity-driven resistance mechanisms (eg SLC7A11-mediated ferroptosis evasion); notably, no Phase I/II clinical trials for matrine or its derivatives in cancer therapy have been registered to date. Future research should prioritize the development of intelligent delivery systems (DNA origami nanorobots, magnetically guided micro/nano-swimmers), multi-omics-driven precision strategies (spatial metabolomics, single-cell epi-drugomics), and synthetic biology platforms (PROTAC bifunctional molecules, AI-assisted crystal screening). Integrating organ-on-chip technologies and real-world data analytics will accelerate the transformation of matrine-based compounds into next-generation intelligent anticancer agents, offering innovative solutions for comprehensive cancer management.
Keywords: cancer therapy, matrine, multi-pathway regulation, nanodelivery systems, precision medicine, synthetic biology
Department of Thoracic Surgery, Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan Province, 646600, People’s Republic of China
Correspondence: Jiangtao Pu, Department of Thoracic Surgery, Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan Province, 646600, People’s Republic of China, Email 19164172037@163.com
Abstract: Matrine and its derivatives, as multi-target natural alkaloids, exhibit synergistic antitumor effects through the regulation of core oncogenic pathways including Wnt/β-catenin, MAPK/ERK, and PI3K/AKT/mTOR. These compounds inhibit tumor proliferation by suppressing epithelial-mesenchymal transition (EMT), inducing programmed cell death (apoptosis, autophagy, and pyroptosis), and remodeling the tumor immune microenvironment. Preclinical studies demonstrate that third-generation derivatives (e.g.MT-26, YF-18) enhance therapeutic efficacy by targeting DNMT1/HDAC6 dual inhibition and activating the NLRP3/caspase-1 pyroptosis pathway, achieving tumor suppression rates of 60– 78% in pancreatic and liver cancer patient-derived xenograft (PDX) models while overcoming chemotherapy resistance. However, preclinical-to-clinical translation faces challenges such as low bioavailability, off-target toxicity (e.g.hepatotoxicity via JNK/c-Jun activation), and tumor heterogeneity-driven resistance mechanisms (eg SLC7A11-mediated ferroptosis evasion); notably, no Phase I/II clinical trials for matrine or its derivatives in cancer therapy have been registered to date. Future research should prioritize the development of intelligent delivery systems (DNA origami nanorobots, magnetically guided micro/nano-swimmers), multi-omics-driven precision strategies (spatial metabolomics, single-cell epi-drugomics), and synthetic biology platforms (PROTAC bifunctional molecules, AI-assisted crystal screening). Integrating organ-on-chip technologies and real-world data analytics will accelerate the transformation of matrine-based compounds into next-generation intelligent anticancer agents, offering innovative solutions for comprehensive cancer management.
Keywords: cancer therapy, matrine, multi-pathway regulation, nanodelivery systems, precision medicine, synthetic biology